24/7 Market News Snapshot 25 August, 2025 – scPharmaceuticals Inc. Common Stock (NASDAQ:SCPH)

August 25, 2025

DENVER, Colo., 25 August, 2025 (www.247marketnews.com) – (NASDAQ:SCPH) are discussed in this article.
scPharmaceuticals Inc. (SCPH) is poised for growth following its recent acquisition by MannKind Corporation, which reinforces MannKind’s strategic commitment to tackling unmet medical needs within the cardiorenal sector. The definitive merger agreement involves MannKind purchasing all outstanding shares of scPharmaceuticals’ common stock at $5.35 per share, a price reflecting a 36% premium over the average trading price in the last 90 days. The deal may yield additional value through contingent rights, potentially reaching $6.35 per share contingent on the successful achievement of specified regulatory and sales milestones.

This acquisition strategically enhances MannKind’s commercial portfolio, incorporating revenue streams that include the innovative FUROSCIX® on-body infuser. This FDA-approved solution addresses fluid overload in patients suffering from chronic heart failure and chronic kidney disease. By integrating scPharmaceuticals’ product offerings, MannKind positions itself for considerable growth, with anticipated annual sales surpassing $370 million based on recent data.

MannKind’s focus extends beyond mere revenue generation; this merger is set to enrich its alignment with the evolving demands in the cardiometabolic landscape. As MannKind prepares for the submission of the FUROSCIX ReadyFlow Autoinjector in the third quarter of 2025, the organization is committed to enhancing patient access and convenience, thereby elevating healthcare delivery standards.

Michael Castagna, CEO of MannKind, emphasized the importance of this acquisition, noting the enhancement of innovation in therapies coupled with a diversification of revenue streams. Similarly, John Tucker, CEO of scPharmaceuticals, optimistically remarked on the synergistic potential of both companies in improving patient outcomes through advanced, patient-centered treatments. As this strategic merger unfolds, it holds significant promise for advancing healthcare solutions for patients facing complex medical challenges.

Related news for (SCPH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.